ALNY:NSD-Alnylam Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 243.53

Change

-3.22 (-1.30)%

Market Cap

USD 31.94B

Volume

0.83M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.52 (+0.73%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.87 (-1.99%)

USD 76.39B
ARGX argenx NV ADR

-2.06 (-0.33%)

USD 40.41B
ONC BeiGene, Ltd.

-26.27 (-9.67%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.22 (+0.65%)

USD 18.65B
SMMT Summit Therapeutics PLC

-1.56 (-7.54%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-10.02 (-3.13%)

USD 14.37B
INCY Incyte Corporation

-3.24 (-4.41%)

USD 14.22B
INSM Insmed Inc

-5.26 (-6.45%)

USD 13.70B
BMRN Biomarin Pharmaceutical Inc

-0.14 (-0.20%)

USD 13.58B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

-0.13 (-0.75%)

N/A
CURG:LSE VanEck Genomics and Healt.. 4.93 % 0.00 %

-0.11 (-0.75%)

USD 5.16M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 3.89 % 0.00 %

-0.12 (-0.75%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.89 % 0.00 %

-0.09 (-0.75%)

USD 9.42M
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

-0.01 (-0.75%)

N/A
CURE:AU ETFS S&P Biotech ETF 2.52 % 0.00 %

+1.25 (+-0.75%)

USD 0.04B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

+0.26 (+-0.75%)

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

+0.12 (+-0.75%)

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.07 % 0.00 %

-0.21 (-0.75%)

USD 0.05B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

+0.44 (+-0.75%)

N/A
DOCT:SW L&G Healthcare Breakthrou.. 1.91 % 0.00 %

+0.07 (+-0.75%)

USD 0.07B
EQJS:LSE Invesco NASDAQ Next Gener.. 1.89 % 0.00 %

-8.00 (-0.75%)

USD 0.05B
TMFX Motley Fool Next Index ET.. 1.65 % 0.00 %

-0.44 (-0.75%)

USD 0.03B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

-1.80 (-0.75%)

N/A
THNZ:XETRA 0.87 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-2.12 (-0.75%)

USD 0.39B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-2.14 (-0.75%)

USD 0.06B
ETHO Amplify ETF Trust 0.00 % 0.45 %

-1.15 (-0.75%)

USD 0.18B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.96 (-0.75%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-2.79 (-0.75%)

USD 6.39B
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-8.59 (-0.75%)

USD 0.77B
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.35 (-0.75%)

USD 0.07B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.49 (-0.75%)

USD 0.05B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+-0.75%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.03 (-0.75%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+-0.75%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-3.11 (-0.75%)

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.05 (-0.75%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.01 (-0.75%)

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

-0.66 (-0.75%)

USD 0.68B
QQQN 0.00 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-12.90 (-0.75%)

USD 8.65M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

+0.04 (+-0.75%)

USD 8.62M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.50 (-0.75%)

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

-0.16 (-0.75%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.49% 77% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.49% 77% C+ 74% C
Trailing 12 Months  
Capital Gain 62.31% 92% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.31% 92% A 91% A-
Trailing 5 Years  
Capital Gain 107.72% 90% A- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.72% 90% A- 84% B
Average Annual (5 Year Horizon)  
Capital Gain 15.96% 64% D 70% C-
Dividend Return 15.96% 64% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.66% 88% B+ 64% D
Risk Adjusted Return 55.69% 96% N/A 80% B-
Market Capitalization 31.94B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.